A method for prognosing non-small cell lung cancer (NSCLC) relapse in a cancer patient comprising: a) determining the level of expression of a first biomarker, hsa-miR-513b, in a sample from the cancer patient; b) comparing the level of expression of said first biomarker in said sample to the level of expression of said first biomarker in a sample from a first reference patient having a history of a NSCLC diagnosis, wherein said first reference patient has been determined to have a good prognosis of no NSCLC relapse; c) comparing the level of expression of said first biomarker in said sample to the level of expression of said first biomarker in a sample from a second reference patient having a history of a NSCLC diagnosis, wherein said second reference patient has been determined to have a poor prognosis of no NSCLC relapse; and d) determining the prognosis of NSCLC relapse in said cancer patient, wherein: i) a determination that the level of expression of said first biomarker in said sample from said cancer patient is similar to the level of expression of said first biomarker in said sample from said first reference patient indicates a good prognosis of no NSCLC relapse in said cancer patient, and ii) a determination that the level of expression of said first biomarker in said sample from said cancer patient is similar to the level of expression of said first biomarker in said sample from said second reference patient indicates a poor prognosis of no NSCLC relapse in said cancer patient. a) determining the level of expression of a first biomarker, hsa-miR-513b, in a sample from the cancer patient; b) comparing the level of expression of said first biomarker in said sample to the level of expression of said first biomarker in a sample from a first reference patient having a history of a NSCLC diagnosis, wherein said first reference patient has been determined to have a good prognosis of no NSCLC relapse; c) comparing the level of expression of said first biomarker in said sample to the level of expression of said first biomarker in a sample from a second reference patient having a history of a NSCLC diagnosis, wherein said second reference patient has been determined to have a poor prognosis of no NSCLC relapse; and d) determining the prognosis of NSCLC relapse in said cancer patient, wherein: i) a determination that the level of expression of said first biomarker in said sample from said cancer patient is similar to the level of expression of said first biomarker in said sample from said first reference patient indicates a good prognosis of no NSCLC relapse in said cancer patient, and ii) a determination that the level of expression of said first biomarker in said sample from said cancer patient is similar to the level of expression of said first biomarker in said sample from said second reference patient indicates a poor prognosis of no NSCLC relapse in said cancer patient. i) a determination that the level of expression of said first biomarker in said sample from said cancer patient is similar to the level of expression of said first biomarker in said sample from said first reference patient indicates a good prognosis of no NSCLC relapse in said cancer patient, and ii) a determination that the level of expression of said first biomarker in said sample from said cancer patient is similar to the level of expression of said first biomarker in said sample from said second reference patient indicates a poor prognosis of no NSCLC relapse in said cancer patient.